Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies
Sponsor: Fred Hutchinson Cancer Center
Listed as NCT06817889, this PHASE2 trial focuses on Autoimmune Disease and Hematopoietic and Lymphatic System Neoplasm and remains actively recruiting participants. Sponsored by Fred Hutchinson Cancer Center, it has been updated 9 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 4 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fred Hutchinson Cancer Center
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .